Antiangiogenesis agents avastin and erbitux enhance the efficacy of photodynamic therapy in a murine bladder tumor model

Lasers in Surgery and Medicine

Volumn 43, Issue 7, 2011, Pages 651-662

  Bhuvaneswari, Ramaswamy ^a   Yuen, Gan Yik ^b   Chee, Soo Khee ^a   Olivo, Malini ^c,d,e  

^a DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^b NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

^c NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^e AGENCY FOR SCIENCE   (Singapore)

Author keywords

angiogenesis; antiangiogenic agents; avastin; bladder cancer; combination therapy; erbitux; photodynamic therapy

Indexed keywords

BEVACIZUMAB; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; HYPERICIN; VASCULOTROPIN;

ADOLESCENT; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLADDER TUMOR; CANCER INHIBITION; CANCER INVASION; CANCER RECURRENCE; CELL MIGRATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; HYPOXIA; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; TUMOR XENOGRAFT; UMBILICAL VEIN ENDOTHELIAL CELL;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOTTING, WESTERN; CELL MOVEMENT; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MALE; MICE; MICE, INBRED BALB C; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; PERYLENE; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; RANDOM ALLOCATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; URINARY BLADDER NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 80052066984     PISSN: 01968092     EISSN: 10969101     Source Type: Journal    
DOI: 10.1002/lsm.21109     Document Type: Article

References (43)

1. Huang Z,. A review of progress in clinical photodynamic therapy. Technol Cancer Res Treat 2005; 4: 283-293. (Pubitemid 40807688)
2. Dolmans DE, Fukumura D, Jain RK,. Photodynamic therapy for cancer. Nat Rev Cancer 2003; 3: 380-387. (Pubitemid 37328858)
3. Juarranz A, Jaen P, Sanz-Rodriguez F, Cuevas J, Gonzalez S,. Photodynamic therapy of cancer. Basic principles and applications. Clin Transl Oncol 2008; 10: 148-154.
4. Pugh CW, Ratcliffe PJ,. Regulation of angiogenesis by hypoxia: Role of the HIF system. Nat Med 2003; 9: 677-684. (Pubitemid 36749216)
5. Folkman J,. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002; 29: 15-18.
6. Ferrara N,. Vascular endothelial growth factor as a target for anticancer therapy. Oncologist 2004; 9 (Suppl 1): 2-10. (Pubitemid 38747842)
7. Herbst RS,. Therapeutic options to target angiogenesis in human malignancies. Expert Opin Emerg Drugs 2006; 11: 635-650. (Pubitemid 44735590)
8. Ciardiello F, Tortora G,. A novel approach in the treatment of cancer: Targeting the epidermal growth factor receptor. Clin Cancer Res 2001; 7: 2958-2970. (Pubitemid 32963812)
9. Colquhoun AJ, Mellon JK,. Epidermal growth factor receptor and bladder cancer. Postgrad Med J 2002; 78: 584-589. (Pubitemid 35333063)
10. Lee JJ, Chu E,. An update on treatment advances for the first-line therapy of metastatic colorectal cancer. Cancer J 2007; 13: 276-281.
11. Seiwert TY, Cohen EE,. Targeting angiogenesis in head and neck cancer. Semin Oncol 2008; 35: 274-285. (Pubitemid 351787696)
12. Folkman J,. The role of angiogenesis in tumor growth. Semin Cancer Biol 1992; 3: 65-71.
13. Lamalice L, Le Boeuf F, Huot J,. Endothelial cell migration during angiogenesis. Circ Res 2007; 100: 782-794. (Pubitemid 46555683)
14. Klemke RL, Leng J, Molander R, Brooks PC, Vuori K, Cheresh DA,. CAS/Crk coupling serves as a "molecular switch" for induction of cell migration. J Cell Biol 1998; 140: 961-972. (Pubitemid 28141232)
15. Albini A,. Tumor and endothelial cell invasion of basement membranes. The matrigel chemoinvasion assay as a tool for dissecting molecular mechanisms. Pathol Oncol Res 1998; 4: 230-241. (Pubitemid 28554963)
16. Albini A, Benelli R,. The chemoinvasion assay: A method to assess tumor and endothelial cell invasion and its modulation. Nat Protoc 2007; 2: 504-511. (Pubitemid 47040014)
17. Ridley AJ, Schwartz MA, Burridge K, Firtel RA, Ginsberg MH, Borisy G, Parsons JT, Horwitz AR,. Cell migration: Integrating signals from front to back. Science 2003; 302: 1704-1709. (Pubitemid 37505725)
18. Carneiro A, Falcao M, Azevedo I, Falcao Reis F, Soares R,. Multiple effects of bevacizumab in angiogenesis: Implications for its use in age-related macular degeneration. Acta Ophthalmol 2009; 87: 517-523.
19. Huang SM, Li J, Harari PM,. Molecular inhibition of angiogenesis and metastatic potential in human squamous cell carcinomas after epidermal growth factor receptor blockade. Mol Cancer Ther 2002; 1: 507-514.
20. Khosravi Shahi, Fernandez P, Pineda I,. Tumoral angiogenesis: Review of the literature. Cancer Invest 2008; 26: 104-108.
21. Bernatchez PN, Soker S, Sirois MG,. Vascular endothelial growth factor effect on endothelial cell proliferation, migration, and platelet-activating factor synthesis is Flk-1-dependent. J Biol Chem 1999; 274: 31047-31054.
22. Shweiki D, Itin A, Soffer D, Keshet E,. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992; 359: 843-845.
23. Dvorak HF, Brown LF, Detmar M, Dvorak AM,. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995; 146: 1029-1039.
24. Weis S, Cui J, Barnes L, Cheresh D,. Endothelial barrier disruption by VEGF-mediated Src activity potentiates tumor cell extravasation and metastasis. J Cell Biol 2004; 167: 223-229. (Pubitemid 39435066)
25. Skobe M, Rockwell P, Goldstein N, Vosseler S, Fusenig NE,. Halting angiogenesis suppresses carcinoma cell invasion. Nat Med 1997; 3: 1222-1227. (Pubitemid 27508822)
26. Vokes SA, Yatskievych TA, Heimark RL, McMahon J, McMahon AP, Antin PB, Krieg PA,. Hedgehog signaling is essential for endothelial tube formation during vasculogenesis. Development 2004; 131: 4371-4380. (Pubitemid 39276203)
27. Grau S, Thorsteinsdottir J, von Baumgarten L, Winkler F, Tonn JC, Schichor C,. Bevacizumab can induce reactivity to VEGF-C and -D in human brain and tumor derived endothelial cells. J Neurooncol
28. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH, Folkman J,. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994; 79: 315-328. (Pubitemid 24324921)
29. Gomer CJ, Ferrario A, Luna M, Rucker N, Wong S,. Photodynamic therapy: Combined modality approaches targeting the tumor microenvironment. Lasers Surg Med 2006; 38: 516-521.
30. Lu C, Kamat AA, Lin YG, Merritt WM, Landen CN, Kim TJ, Spannuth W, Arumugam T, Han LY, Jennings NB, Logsdon C, Jaffe RB, Coleman RL, Sood AK,. Dual targeting of endothelial cells and pericytes in antivascular therapy for ovarian carcinoma. Clin Cancer Res 2007; 13: 4209-4217. (Pubitemid 47105985)
31. Vallbohmer D, Zhang W, Gordon M, Yang DY, Yun J, Press OA, Rhodes KE, Sherrod AE, Iqbal S, Danenberg KD, Groshen S, Lenz HJ,. Molecular determinants of cetuximab efficacy. J Clin Oncol 2005; 23: 3536-3544.
32. Ellis LM, Hoff PM,. Targeting the epidermal growth factor receptor: An important incremental step in the battle against colorectal cancer. J Clin Oncol 2004; 22: 1177-1179. (Pubitemid 41079828)
33. Manzoni M, Rovati B, Ronzoni M, Loupakis F, Mariucci S, Ricci V, Gattoni E, Salvatore L, Tinelli C, Villa E, Danova M,. Immunological effects of bevacizumab-based treatment in metastatic colorectal cancer. Oncology 2010; 79: 187-196.
34. Roda JM, Joshi T, Butchar JP, McAlees JW, Lehman A, Tridandapani S, Carson WE 3rd., The activation of natural killer cell effector functions by cetuximab-coated, epidermal growth factor receptor positive tumor cells is enhanced by cytokines. Clin Cancer Res 2007; 13: 6419-6428. (Pubitemid 350075032)
35. Bhuvaneswari R, Gan YY, Yee KK, Soo KC, Olivo M,. Effect of hypericin-mediated photodynamic therapy on the expression of vascular endothelial growth factor in human nasopharyngeal carcinoma. Int J Mol Med 2007; 20: 421-428.
36. Henderson BW, Gollnick SO, Snyder JW, Busch TM, Kousis PC, Cheney RT, Morgan J,. Choice of oxygen-conserving treatment regimen determines the inflammatory response and outcome of photodynamic therapy of tumors. Cancer Res 2004; 64: 2120-2126. (Pubitemid 38339462)
37. Liang WC, Wu X, Peale FV, Lee CV, Meng YG, Gutierrez J, Fu L, Malik AK, Gerber HP, Ferrara N, Fuh G,. Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF. J Biol Chem 2006; 281: 951-961.
38. Kumar RR, Meenakshi A, Sivakumar N,. Enzyme immunoassay of human epidermal growth factor receptor (hEGFR). Hum Antibodies 2001; 10: 143-147. (Pubitemid 34258593)
39. Gazzaniga P, Gandini O, Giuliani L, Magnanti M, Gradilone A, Silvestri I, Gianni W, Gallucci M, Frati L, Agliano AM,. Detection of epidermal growth factor receptor mRNA in peripheral blood: A new marker of circulating neoplastic cells in bladder cancer patients. Clin Cancer Res 2001; 7: 577-583. (Pubitemid 32707981)
40. Solban N, Selbo PK, Sinha AK, Chang SK, Hasan T,. Mechanistic investigation and implications of photodynamic therapy induction of vascular endothelial growth factor in prostate cancer. Cancer Res 2006; 66: 5633-5640. (Pubitemid 43927115)
41. Tsai T, Ji HT, Chiang PC, Chou RH, Chang WS, Chen CT,. ALA-PDT results in phenotypic changes and decreased cellular invasion in surviving cancer cells. Lasers Surg Med 2009; 41: 305-315.
42. Ahmad N, Kalka K, Mukhtar H,. In vitro and in vivo inhibition of epidermal growth factor receptor-tyrosine kinase pathway by photodynamic therapy. Oncogene 2001; 20: 2314-2317. (Pubitemid 32531289)
43. Press MF, Lenz HJ,. EGFR, HER2, and VEGF pathways: Validated targets for cancer treatment. Drugs 2007; 67: 2045-2075. (Pubitemid 47524565)